Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Novartis plans to file for new Lucentis indication in ROP
ROP is a rare and potentially blinding resulted due to abnormal development of retinal blood vessels in premature babies. The company has presented data from a Rainbow phase
ROP is a rare and potentially blinding resulted due to abnormal development of retinal blood vessels in premature babies. The company has presented data from a Rainbow phase
BARDA is part of the U.S. Health and Human Services Office of the Assistant Secretary for Preparedness and Response. OPTN003, nasal nalmefene, is a potent, long-acting opioid antagonist
The approval of Hulio is based on adoption of positive opinion by the Committee for Medicinal Products for Human Use (CHMP). The CHMP determined that development program, including
Under the terms of the agreement, Shield will receive an immediate £11 million upfront payment, is eligible to receive up to €4.5m in short-term development milestones and up
The ACCC promotes competition and fair trade in markets to benefit consumers, businesses, and the community. In May this year, Apotex Australia announced a merger of their Australian
Cancer Genetics will be the surviving entity and expects to remain listed on the Nasdaq Stock Market. This transaction will combine Cancer Genetics’ scale, expansive test portfolio and
The company is restructuring its R&D organization to accelerate the expansion and diversification of its pipeline across severe chronic diseases, in addition to supporting increased investment in transformational
The CLR 131 is an investigational radioiodinated PDC therapy, which exploits the tumor-targeting properties of the firm’s phospholipid ether (PLE) and PLE analogs to selectively deliver radiation to
Respivant will be led by chief executive officer Bill Gerhart, Executive Vice President for Clinical and Regulatory Ahmet Tutuncu, MD, PhD, and Executive Vice President for Development and
Pfizer will evaluate Atomwise’s platform to identify potential drug candidates for up to three target proteins selected by Pfizer. In the agreement, Pfizer will pay a technology access